Compare SPSC & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPSC | IOVA |
|---|---|---|
| Founded | 1987 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 2009 | 2008 |
| Metric | SPSC | IOVA |
|---|---|---|
| Price | $59.46 | $4.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 10 |
| Target Price | ★ $100.89 | $9.11 |
| AVG Volume (30 Days) | 816.3K | ★ 18.2M |
| Earning Date | 05-15-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.59 | 14.84 |
| EPS | ★ 2.46 | N/A |
| Revenue | ★ $220,566,000.00 | N/A |
| Revenue This Year | $8.91 | $49.14 |
| Revenue Next Year | $7.30 | $51.69 |
| P/E Ratio | $24.61 | ★ N/A |
| Revenue Growth | ★ 14.11 | N/A |
| 52 Week Low | $52.56 | $1.64 |
| 52 Week High | $153.16 | $5.63 |
| Indicator | SPSC | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 36.64 | 54.36 |
| Support Level | $52.56 | $1.99 |
| Resistance Level | $64.46 | $4.34 |
| Average True Range (ATR) | 2.58 | 0.47 |
| MACD | 1.17 | -0.05 |
| Stochastic Oscillator | 59.03 | 24.18 |
SPS Commerce Inc is a provider of cloud-based supply chain management services for retailers, grocers, distributors, suppliers, and logistics firms to increase supply chain performance, optimize inventory levels and sell-through, reduce operational costs, improve order visibility, and satisfy consumer demands for a seamless omnichannel experience. Its solutions are delivered through the SPS Commerce platform and provide integrations and retail performance analytics to its customers. Its products are; Fulfillment, Analytics, and Other products like Assortment and Community also it provides one-time services such as professional services and testing and certification. The group derives revenue from subscription-based recurring revenue services.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.